The most common complication faced by cancer patients is chemotherapy overdose. The drug used in chemotherapy 5-fluorouracil (5-FU) or capecitabine is known for causing severe toxicity affecting the cardiac or central nervous system and allergic reactions in patients.
The Food and Drug Administration (FDA) has recently approved a drug called Vistogard (uridine triacetate) for treating patients suffering from chemotherapy overdose. The drug has showed positive results in its final clinical trial.
‘FDA approves Vistogard or uridine triacetate for treating patients suffering from chemotherapy overdose.’
AdvertisementUridine triacetate was tested on 135 adult and pediatric patients in two separate trials who had either overdosed on 5-FU or experienced life-threatening adverse events within 4 days of receiving 5-FU infusion therapy. Of those patients treated for overdose, 97% were alive after 30 days. Of those treated for toxicities, 89% were alive at 30 days.
The drug developed by Wellstat Therapeutics should be taken soon after overexposure - regardless of whether symptoms are present or early onset of severe toxicities, including severe mucositis, fever, diarrhea, or rash.